Clinical trial
An Open-Label, Multi-Centre, Extension Study, evaluating the Long-Term Safety and Tolerability of Different Three-Month Degarelix Dosing Regimens, 240 mg (40 mg/mL), 240 mg (60 mg/mL), in Patients with Prostate Cancer.
To evaluate the safety and tolerability of different dosing regimens
| Category | Value |
|---|---|
| Study start date | 2006-01-24 |